Skip to content

Laparoscopic Versus Transvaginal Approaches in Repair of Uterine Niche: A Randomized Controlled Trial

Laparoscopic Versus Transvaginal Approaches in Repair of Uterine Niche: A Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04241107
Acronym
isthmocele
Enrollment
50
Registered
2020-01-27
Start date
2020-03-31
Completion date
2022-03-31
Last updated
2020-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine Niche

Keywords

Cesarean Scar defect

Brief summary

The treatment of uterine niche ranges from clinical management with expectant or pharmacological treatment, surgical treatment. Approaches for repair include Laparotomy, laparoscopy , hysteroscopy , vaginal. The decision to treat takes into consideration the size of the defect, presence of symptoms, secondary infertility and plans of pregnancy. All of the approaches have its merits and debates. There is ongoing debate regarding the best surgical approach to managing this condition. To date no randomized controlled trials have been published to settle this debate. Our study aim is to to evaluate which surgical approach is a preferable option, this study will be conducted to compare the Laparoscopic and transvaginal approaches in several regards, including, operation time, blood loss, perioperative complications, hospital stay length, postoperative increase in residual myometrial thickness during follow-up , clinical efficacy(percentage of patients who subject improvement of symptoms)

Interventions

PROCEDURELaparoscopic repair of Uterine niche

Repair of uterine niche through Laparoscopic approach.

PROCEDURETransvaginal repair of Uterine niche

Repair of uterine niche through Transvaginal approach.

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 43 Years
Healthy volunteers
No

Inclusion criteria

\- Patients who have uterine niche (defined as myometrial discontinuity or a hypoechoic triangle in the myometrium of the anterior uterine wall at the site of hysterotomy presented in transvaginal ultrasound or sonohysterography examination in non-pregnant women) ,with one or more previous caesarean section Who are: 1. Symptomatic i.e patients having one or more of the following symptoms: 1. Postmenstrual spotting (defined as more than 2 days of brownish discharge at the end of menstruation with a total length of menstruation (including spotting) of more than 7 days, or intermenstrual bleeding which starts within 5 days after the end of menstruation. \[15\]), 2. Secondary Dysmenorrhea( defined as the pain or discomfort associated with menstruation) 3. deep dyspareunia(deep genital pain associated with sexual intercourse) 4. Chronic pelvic pain can be defined as intermittent or constant pain in the lower abdomen or pelvis of a woman of at least 6 months in duration, not occurring exclusively with menstruation or intercourse and not associated with pregnancy. 5. secondary infertility (defined by the World Health Organization as, -when a woman is unable to bear a child, either due to the inability to become pregnant or the inability to carry a pregnancy to a live birth following either a previous pregnancy or previous ability to carry a pregnancy to a live birth.) 2. Asymptomatic patients with one of the followings: the residual myometrial thickness over the niche less than 3 mm previous history of Cesarean Section scar ectopic pregnancy (not managed by resection and repair) 3. who accept to participate the study.

Exclusion criteria

1. Asymptomatic patients with residual myometrial thickness more than 3 mm. 2. No previous Cesarean section. 3. If the patients symptoms presented before Cesarean section. 4. Presence of other pathology that explain patient symptoms 1. sub mucous fibroid 2. cervical-Endometrial carcinoma 3. Endometrial hyperplasia 4. Coagulation defect. 5. Presence of pathology that necessitate laparotomy. 6. Patient who refuse to participate the study.

Design outcomes

Primary

MeasureTime frameDescription
Clinical efficacy3 month postoperativeNumber of patients who subject clinical improvement of pre-operative symptoms
Post-operative increase in residual myometrial thickness3 month postoperativedifference between pre-operative & post-operative residual myometrial thickness

Secondary

MeasureTime frameDescription
Duration of operationbaseline( During operation)duration from anesthesia till end of operation
Blood lossbaseline( During operation)estimated blood loss during operation(towels , suction container)
Intra-operative complicationbaseline( During operation)complication during the operation

Countries

Egypt

Contacts

Primary ContactAbdulrahman Muhammad Rageh, M.Sc
Abdulrahmanrageh.26.9@gmail.com02 01005056259

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026